Trial reportBMC cardiovascular disorders2025
Innovative nitric oxide delivery technology for postoperative pulmonary hypertension in congenital heart disease patients: a clinical trial.
Trial report in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInhaled nitric oxide (iNO) is a selective pulmonary vasodilator with therapeutic benefits for pulmonary hypertension patients. Traditional cylinder-based iNO delivery systems are costly and complex, creating unmet medical needs. This study evaluated the safety and efficacy of a novel electrochemical nitric oxide generator (ENG) for administering iNO to adult patients with congenital heart disease-associated pulmonary arterial hypertension (CHD-PAH) in China following cardiac surgery.
methodsTwenty patients with CHD-PAH, undergoing cardiac surgery, were enrolled. Two hours post-surgery, when systemic circulation was stable, iNO was delivered via the ENG at 20 ppm. Clinical data were recorded, and iNO therapy was discontinued upon extubation. Safety, gas exchange, and hemodynamic parameters were analyzed before and at 2, 4, and 6 h post-treatment.
resultsAll patients received iNO treatment successfully and were discharged. The NO concentration remained stable, unaffected by ventilator settings, and NO
conclusionThe ENG provided stable NO delivery, ensuring safety and efficacy in postoperative adult CHD-PAH patients. It was associated with improvements of hemodynamics and gas exchange without systemic side effects, offering a compact, efficient, and cost-effective alternative to traditional iNO delivery systems. This research was registered with the Clinical Trial Registry at http://www.chictr.org.cn , under the registration number ChiCTR2400091214. The submission occurred on March 25, 2024, and the registration was made publicly available on October 23, 2024.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.